Clearmind Medicine shares jump 13.10% premarket after announcing intranasal MEAI formulation partnership with Polyrizon.

Clearmind Medicine Inc. (CMND) surged 13.10% in premarket trading following the announcement of a strategic development agreement with Polyrizon Ltd. to advance an intranasal formulation of its proprietary non-hallucinogenic neuroplastogen MEAI. The collaboration leverages Polyrizon’s hydrogel technology to enhance MEAI’s bioavailability, therapeutic efficacy, and patient usability for treating addiction-related and CNS disorders. The partnership is expected to accelerate clinical development by optimizing nasal delivery, bypassing first-pass metabolism, and enabling faster absorption. Clearmind’s CEO highlighted the alignment with the company’s mission to innovate in unmet medical needs, reinforcing investor confidence in the pipeline’s potential. The news directly correlates with the stock’s upward movement, reflecting optimism around improved drug delivery mechanisms and clinical progress.